NCT05546125

a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China

A Non-interventional Study to Further Characterize the Safety and Effectiveness of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China in a Real World Setting

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Pfizer Pharmaceuticals Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This observational study will involve analysis of data collected by the National Rare Disease Registry or medical records .The study will describe outcomes only in PAH(Pulmonary arterial hypertension) patients treated with sildenafil; there will be no comparison with another treatment group. Approximately 100 adults with PAH will be recruited in China hospitals This NIS(non-interventional study) data will be recorded by a physician in the medical records, during the patients' clinical visits, and in the electronic Case Report Forms (CRF).

Conditions

• Pulmonary Arterial Hypertension (PAH)

Interventions

Type	Name	Description
OTHER	as per Physician's prescription	Participants need to take the Revatio as per Physician's prescription

Timeline

• Start date: 2021-12-23
• Primary completion: 2023-02-27
• Completion: 2023-02-27
• First posted: 2022-09-19
• Last updated: 2023-04-18

Locations

7 sites across 1 country: China